Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2019

View Archived Issues

Ketotifen-releasing contact lens for the management of ocular allergy itch

Samumed presents phase IIb results for SM-04690 in knee osteoarthritis

New epigenetic immunomodulator for SWI/SNF-deficient cancers presented

Patient enrollment ongoing in first-in-human study of SL-279252

COM-701 safe in initial cohorts of phase I study

G protein-coupled receptor 35 agonists described by Okayama University and Kogakuin University

Bio Pep synthesizes new therapeutic oligopeptides

Arresting the transition from acute to chronic pain

New IL-10 production enhancers patented by Daiichi Sankyo

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent RORC agonists

Keeping bacteria from genome gambling slows resistance evolution

DE Shaw Research discovers GTPase KRas inhibitors

Arcus Biosciences presents AB-680, a potent and selective inhibitor of CD73

ITRI-E-212 demonstrates promising safety and IOP-lowering effects in vivo

Eli Lilly presents population PK data for LY-3295668 erbumine in patients with advanced solid tumors

Phase Ia data presented for anti-EGFR antibody-drug conjugate AVID-100

DNA methylation marks in ELOVL2 gene as promising epigenetic biomarkers of early-stage AD

CE mark for radioenhancer Hensify for locally advanced soft tissue sarcoma

Celltrion and iProgen partner to develop ADCs

Phase II trial evaluates use of radiosensitizer AGuIX in brain metastases

First-in-human study finds ONO-5788 well tolerated in single ascending doses

New phase I trial studies PD-1 antibody AMG-404 in advanced solid tumors

United Therapeutics discontinues development of esuberaprost based on BEAT results in PAH

AstraZeneca PI3Kgamma inhibitor AZD-3458 reverts tumor resistance to immunotherapy in vivo

Preclinical study of DLL3/CD3 IgG-like T-cell engager for small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...